Clinical trials: Adrenocortical Adenoma
Adrenal Tumor, Adrenal Incidentaloma
CRISAL Study:Cancer Risk In Secreting Adrenal Lesions
The aim of the present study is to report the cancer risk in secreting adrenal lesions. Secondary aims: to compare the incidence of cancer in secreting versus non-secreting adrenal lesions, in order to evaluate whether adrenal…
- Conditions
- Adrenal Tumor, Adrenal Incidentaloma, Surgery
- Trial name
- CRISAL (NCT06520111)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Roma La Sapienza
Primary Aldosteronism, Essential Hypertension
The Plasma Metabolomics Profiling of Primary Aldosteronism
Primary aldosteronism (PA), characterized by overt renin-independent aldosterone production, is the most common form endocrine hypertension.
- Conditions
- Primary Aldosteronism, Essential Hypertension, Idiopathic Aldosteronism, Aldosterone-producing Adenoma
- Trial name
- NCT06500000
- Testing
- liquid chromatography-mass spectrometry (LC/MS)
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Third Military Medical University
Adrenal Tumor, Adrenal Adenoma
Laparoscopic Adrenalectomy for Large Adrenal Tumors.
Laparoscopic adrenalectomy is the treatment of choice for the benign tumor of less than 6 cm. However, this is an ongoing debate that exact cut-off value of tumor size for LA.
- Trial name
- NCT03830593
- Testing
- Laparoscopic Adrenalectomy
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- Samsun Liv Hospital
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with…
- Conditions
- Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
- Trial name
- IMPACT-MACS (NCT07361874)
- Testing
- Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Adrenocortical Adenoma, Endometrial Stromal Sarcomas
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
To provide medical follow-up to patients exposed to BGG492 for more than 28 days in study CBGG492A2207 (NCT 01147003) and/or CBGG492A2212 (NCT 01338805).
- Trial name
- NCT02150213
- Testing
- MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram
- Where
- 20 sites in United States, Germany and 4 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome, Adrenal Incidentalomas
Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?
Background: The evaluation for hypercortisolism includes an overnight 1mg dexamethasone (DXM) suppression test. An important shortcoming is the diagnostic specificity of only 80%, which is likely due to inter-individual…
- Conditions
- Cushing's Syndrome, Adrenal Incidentalomas, Alcoholism, Obesity
- Trial name
- DXM (NCT01504555)
- Where
- 4 sites in Norway
- Volunteers
- 300 people
- Sponsor
- Haukeland University Hospital
Mild Autonomous Cortisol Secretion (MACS)
Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma
The aim of the proposed study is to estimate the incidence of Mild Autonomous Cortisol Secretion (MACS) in patients with Adrenal Incidentaloma (AI) and evaluate the available diagnostic tests to determine the most sensitive and…
- Trial name
- MACS (NCT06344143)
- Testing
- Various labs and imaging tests
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Cleveland Clinic
Atrial Fibrillation, Atrial Flutter
Prevalence of Primary Aldosteronism in Hypertensive Patients Presenting With Atrial Flutter or Fibrillation
Primary objective of the PAPPHY Study is to establish the prevalence of primary aldosteronism (PA) in consecutive hypertensive patients referred for 'lone' paroxysmal, persistent or permanent atrial flutter or fibrillation (AFF).
- Conditions
- Atrial Fibrillation, Atrial Flutter, Aldosteronism
- Trial name
- PAPPHY (NCT01267747)
- Where
- 2 sites in Italy
- Volunteers
- 411 people
- Sponsor
- University Hospital Padova
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Hyperaldosteronism; Primary, Primary Aldosteronism Due to Aldosterone Producing Adenoma
Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)
The goal of this project is to improve the diagnostic pathway for patients with primary aldosteronism, by validating non-invasive biomarkers coupled with routine computed tomography imaging.
- Trial name
- NCT07297745
- Testing
- Hybrid hormones
- Where
- 4 sites in Singapore
- Volunteers
- 120 people
- Sponsor
- Changi General Hospital
Primary Hyperaldosteronism
11C-Metomidate PET Versus Adrenal Vein Sampling in Primary Aldosteronism
Rationale: Primary hyperaldosteronism (PA) is the most frequent and possibly curable form of secondary hypertension. The diagnosis and targeted treatment of PA is essential because of high vascular morbidity associated with PA as…
- Trial name
- MIA (NCT01567111)
- Testing
- 11C-Metomidate Positron Emission Tomography
- Where
- 3 sites in Finland
- Volunteers
- 40 people
- Sponsor
- Helsinki University Central Hospital
Adrenal Myelolipoma
Adrenal Myelolipomas Case Series
Six cases (72 years old female patient, 63 years old male patient, 57 years old female patient, 61 years old female, 72 years old female and 56 years old female) of clinically and radiologically suspected cases of symptomatic…
- Trial name
- NCT06913842
- Where
- Mexico
- Volunteers
- 6 people
- Sponsor
- Instituto Mexicano del Seguro Social
Primary Aldosteronism
Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism
The project is aimed to determine the value of synacthen infusion on the results of adrenal venous sampling in patients examined for primary aldosteronism
- Trial name
- ISIRA (NCT02127840)
- Testing
- Synacthen infusion during adrenal venous sampling
- Where
- Czechia
- Volunteers
- 40 people
- Sponsor
- Charles University, Czech Republic
Aldosterone-producing Adenoma, Radiofrequency Ablation
Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma
The purpose of this study is to retrospectively and prospectively analyze the efficacy and safety of ultrasound-guided radiofrequency ablation and laparoscopic adrenalectomy in the treatment of aldosterone-producing adenoma…
- Trial name
- NCT05991856
- Testing
- radiofrequency ablation, laparoscopic adrenalectomy, Hypotensive Drugs
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Pheochromocytoma, Adrenal Incidentaloma
Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue
To investigate the effect of catecholamine excess on brown fat. To evaluate the effect of brown fat on energy expenditure and lipid and glucose metabolism
- Trial name
- NCT01949714
- Testing
- Removal of adrenal tumor
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- University of Aarhus
Adrenal Gland Neoplasm, Hypertension
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Background: The adrenal gland makes the hormone aldosterone. This helps regulate blood pressure. An adrenal gland tumor that makes too much aldosterone can cause high blood pressure and low potassium.
- Conditions
- Adrenal Gland Neoplasm, Hypertension, Bone Diseases, Metabolic, Cardiovascular Disease
- Trial name
- NCT03374215
- Where
- United States
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Adrenal Incidentaloma, Cortisol Overproduction
Morbidity and Mortality in Autonomous Cortisol Secretion
Benign enlargements of the adrenal glands (adrenal adenomas) are frequent in adults. In the general population these adenomas are rare in subjects below 40 years of age but at the age of 60 and 80 years the prevalence is 6 and…
- Trial name
- NCT03919734
- Where
- Sweden
- Volunteers
- 4,596 people
- Sponsor
- Region Skane
Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).
- Trial name
- NCT06106295
- Testing
- Metyrapone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic